Back HIV Populations Children & Adolescents

Children & Adolescents

FDA Approves New Tenofovir (Viread) Formulation and Dosing Regimen for HIV+ Children

The U.S. Food and Drug Administration (FDA) and Gilead Sciences last week announced the approval of a new oral powder formulation and new strength tablets of tenofovir (brand name Viread) -- one of the most widely used nucleoside reverse transcriptase inhibitors (NRTIs) in combination antiretroviral regimens -- as well as new dosing recommendations for HIV positive children and adolescents age 2 through 18 years.alt

Read more:

Pediatric Dose Recommendations for Darunavir (Prezista) and Raltegravir (Isentress)

The U.S. Food and Drug Administration (FDA) recently announced the approval of new dose recommendations and easy-to-use formulations of 2 antiretroviral drugs for children with HIV.alt

Read more:

DHHS Issues Updated Pediatric Antiretroviral Treatment Guidelines

On August 11, 2011, the U.S. Department of Health and Human Services (DHHS) issued the latest revision of its Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.alt

Read more:

Teens Should Receive Routine HIV Testing, Says American Academy of Pediatrics

Adolescents and young adults should be offered risk reduction counseling and routine testing in an effort to prevent HIV transmission and to initiate treatment in a timely manner, according to a recent policy statement from the American Academy of Pediatrics (AAP).alt

Read more:

First-line NNRTI and Protease Inhibitor Regimens Work Equally Well for Children with HIV

Initial antiretroviral therapy (ART) regimens containing protease inhibitors and those with non-nucleoside reverse transcriptase inhibitors (NNRTIs) both produced good outcomes for children with HIV, according to research published in the February 1, 2011 advance online edition of Lancet Infectious Diseases. Viral load dropped by a similar amount, but children who started on NNRTIs and those who waited longer to switch were more likely to develop drug resistance.

Read more: